Innovative drug concept stocks are experiencing widespread declines. At the time of writing, Innovent Bio (01801) shares fell 4.9% to HK$72.85. 3SBIO (01530) dropped 3.44% to HK$15.14. SBP Group (01177) declined 3% to HK$4.52. CSPC Pharma (01093) was down 2.49% to HK$7.06.

The market backdrop includes heightened tensions in the Middle East pushing up energy prices, coupled with robust labor market data, which has strengthened market expectations for potential Federal Reserve interest rate hikes within the year.

Macroeconomic and Policy Risks

Analysts have previously highlighted risks, noting that if global and domestic monetary policy adjustments do not meet expectations, it would directly impact the valuation levels and investment environment for the pharmaceutical sector. Growth-oriented segments like innovative drugs and CXO are particularly sensitive to liquidity conditions. A potential delay in the Fed's rate-cutting cycle or slower-than-expected domestic easing measures could lead to tighter market liquidity, directly pressuring valuations in these growth sectors.

Assessing the BINSA Legislation

Furthermore, the U.S. Biosecure Act (BINSA) draft was released on June 2. Analysis suggests that, overall, this BINSA draft is still in its early stages and faces significant hurdles to implementation. The short-term market volatility is seen as more driven by emotional panic rather than a deterioration in fundamentals. Many leading companies with global competitiveness, high compliance barriers, and strong earnings certainty may have been oversold. The view is to actively consider positioning in high-quality innovative drug firms and leaders within the innovative drug industry chain.